The urgency with which pharmaceutical businesses need to meet the rising demands of global healthcare production often does not provide sufficient time to expand operations by increasing their footprint. For producers of medications currently used in the treatment of patients with Covid-19, it is essential to increase production capacity as quickly as possible.
Technology used for liquid-liquid extraction is seen as key in helping to intensify pharmaceutical manufacturing processes as quickly as possible.
Pharmaceutical ingredient manufacturer Farmhispania, has partnered with separation and mixing technology specialists Sulzer, to ramp up its production capabilities in less than two weeks.
The partners identified Sulzer’s agitated Kühni column, or ECR, liquid-liquid extraction technology, as the most ideal solution. The separation system is particularly suitable for this project, as it is designed to handle a high flow rate, which can maximise throughput.
Sulzer was able to utilise its available stock to build an ECR and ensured a prompt delivery to the pharmaceutical manufacturer. Sulzer is also supporting the equipment installation and startup, in an effort to ensure that production is ramped up as quickly as possible.
Farmhispania Group comments that the exceptional circumstances presented by the threat of Covid-19 motivated the company to work with great urgency in the interest of the public good. The prompt delivery of Sulzer Chemtech’s separation technology allowed for the timely expansion of its operations and the delivery of high volumes of drugs to support the recovery of coronavirus patients in critical condition.
EMAIL THIS ARTICLE SAVE THIS ARTICLE
To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here
